featured
Association of Risankizumab Concentration and IL-22 Levels With Clinical and Biochemical Remission of Crohn's Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Gastroenterology and Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Risankizumab Concentration but not IL-22 Levels Are Associated With Clinical and Biochemical Remission in Patients With Crohn's Disease
Clin. Gastroenterol. Hepatol. 2024 Nov 01;22(11)2340-2343.e2, X Roblin, E Moschetti, M Barrau, AS Cheifetz, K Papamichael, S PaulFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.